In the studies reported, SF1126 showed favorable pharmacokinetics and pharmacodynamic effects as indicated by inhibition of downstream signaling elements both in vitro and in vivo. In addition, SF1126 displayed potent antitumor and antiangiogenic activity in vivo, in mouse models, against a variety of human cancer cell types, including prostate, breast, neuroblastoma, and glioblastoma.
SF1126 also significantly enhanced the activity of docetaxel in a combination regiment in a prostate cancer model. SF1126 differs from other known PI3K inhibitors in that it has a homing feature designed to localize more drug in the tumor compartment.
Ed Jacobs, president and CEO of Semafore, said: “SF1126 continues to support the paradigm shift in cancer treatment that will see the application of highly targeted therapeutic drugs that inhibit the powerful PI3K pathway.”